ReviewInternational journal of molecular sciences2021
Activity of Selected Group of Monoterpenes in Alzheimer's Disease Symptoms in Experimental Model Studies-A Non-Systematic Review.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 45 citations in OpenAlex.
- Neuroprotective Effects and Mechanisms of Carvacrol and Thymol in Alzheimer's Disease: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Unlocking the Power of Plant-Derived Natural Products: Therapeutic Benefits for Cognitive Health and Neuropsychiatric Symptoms in Dementia-Related Diseases.Plants (Basel, Switzerland) · 2026Review
- Neurocognitive and Memory-Enhancing Effect ofPharmaceutics · 2026Article
- Comparative Kinetic Modeling and Mathematical Analysis of Monoterpene Release from Nanocarrier Systems.AAPS PharmSciTech · 2026Article
- Anti-Neuroinflammation Activity of Essential Oils and Fatty Acids.Food science & nutrition · 2026Review
- Article
- Linalool May Exert Neuroprotective Effects Against Cadmium-Induced Hippocampal Neurodegeneration by Regulating the 4-HNE/NF-κB Signaling Pathway.Biological trace element research · 2025Article
- Analysis of Pharmacological Properties ofLife (Basel, Switzerland) · 2025Review
- Predicting nepetalactone accumulation in Nepeta persica using machine learning algorithms and geospatial analysis.Scientific reports · 2025Article
- Modulatory Effects ofAntioxidants (Basel, Switzerland) · 2025Review
- Biological Activity of Monoterpene-Based Scaffolds: A Natural Toolbox for Drug Discovery.Molecules (Basel, Switzerland) · 2025Review
- Plant-Derived Monoterpene Therapies in Parkinson's Disease Models: Systematic Review and Meta-Analysis.Plants (Basel, Switzerland) · 2025Review
- Optimization of a Pressurized Extraction Process Based on a Ternary Solvent System for the Recovery of Neuroprotective Compounds fromInternational journal of molecular sciences · 2024Article
- Article
- Rosiridin Protects Against Aluminum Chloride-Induced Memory Impairment via Modulation of BDNF/NFκB/PI3K/Akt Pathway in Rats.Medicina (Kaunas, Lithuania) · 2024Article
- Exploring the effect of gut microbiome on Alzheimer's disease.Biochemistry and biophysics reports · 2024Review
- Neuroprotective effects of alpha-pinene against behavioral deficits in ketamine-induced mice model of schizophrenia: Focusing on oxidative stress status.IBRO neuroscience reports · 2024Article
- A comprehensive review of the botany, phytochemistry, pharmacology, and toxicology of Murrayae Folium et Cacumen.Frontiers in pharmacology · 2024Review
- Essential Oils in Cervical Cancer: Narrative Review on Current Insights and Future Prospects.Antioxidants (Basel, Switzerland) · 2023Review
- Chemo- and bio-informatics insight into anti-cholinesterase potentials of berries and leaves of Myrtus communis L., Myrtaceae: an in vitro/in silico study.BMC complementary medicine and therapies · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is the leading cause of dementia and cognitive function impairment. The multi-faced character of AD requires new drug solutions based on substances that incorporate a wide range of activities. Antioxidants, AChE/BChE inhibitors, BACE1, or anti-amyloid platelet aggregation substances are most desirable because they improve cognition with minimal side effects. Plant secondary metabolites, used in traditional medicine and pharmacy, are promising. Among these are the monoterpenes-low-molecular compounds with anti-inflammatory, antioxidant, enzyme inhibitory, analgesic, sedative, as well as other biological properties. The presented review focuses on the pathophysiology of AD and a selected group of anti-neurodegenerative monoterpenes and monoterpenoids for which possible mechanisms of action have been explained. The main body of the article focuses on monoterpenes that have shown improved memory and learning, anxiolytic and sleep-regulating effects as determined by in vitro and in silico tests-followed by validation in in vivo models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.